title: Novel approaches in the treatment of allergic rhinitis.
abstract: OBJECTIVE
  The increasing prevalence of allergic rhinitis, its impact on individual quality of life and social costs, as well as its role as a risk factor for asthma, underline the need for improved treatment options for this disorder. We reviewed the recent literature published in English, dealing with relevant and appropriately controlled clinical trials on the treatment of allergic rhinitis.
  
  
  RESULTS
  In addition to well established pharmacological therapies with antihistamines, corticosteroids, decongestants and mast cell stabilizers, new therapeutic options become increasingly important, including leukotriene modifiers, anti-immunoglobulin E antibodies, phosphodiesterase inhibitors and intranasal heparin; there also exist new developments in appropriate allergen specific immunotherapy.
  
  
  CONCLUSIONS
  Promising results, both with established and novel treatment options, are communicated, but further studies are still necessary to confirm these data.
authors.affiliation: Institute of Clinical Pharmacology, Head and Neck Surgery, Faculty of Clinical Medicine Mannheim, Heidelberg University, Mannheim, Germany.
authors.forename: Armin
authors.initials: A
authors.lastname: Schultz
authors.forename: Boris Alexander
authors.initials: BA
authors.lastname: Stuck
authors.forename: Martin
authors.initials: M
authors.lastname: Feuring
authors.forename: Karl
authors.initials: K
authors.lastname: Hörmann
authors.forename: Martin
authors.initials: M
authors.lastname: Wehling
mesh_terms: D000281:Administration, Intranasal; D000906:Antibodies / Q000627:therapeutic use; D003888:Desensitization, Immunologic; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000628:therapy*
chemical_list: D000906:Antibodies; D020024:Leukotriene Antagonists; D010726:Phosphodiesterase Inhibitors; D007073:Immunoglobulin E; D006493:Heparin